One or more concentrated low-viscosity solutions of alkaline earth alkoxide compounds M(OCH.sub.2R.sup.6).sub.2-a-b(OR.sup.7).sub.a[O(CHR.sup.8).sub.nOR.sup.9].sub.b in mixture with a metal alkyl compound M(R.sup.10R.sup.11) in an aprotic solvent and related methods are disclosed herein.

One or more concentrated low-viscosity solutions of alkaline earth alkoxide compounds M(OCH.sub.2R.sup.6).sub.2-a-b(OR.sup.7).sub.a[O(CHR.sup.8).sub.nOR.sup.9].sub.b in mixture with a metal alkyl compound M(R.sup.10R.sup.11) in an aprotic solvent and related methods are disclosed herein.

The present invention provides a process for preparing 6-isopropenyl-3-methyl-9-decenyl acetate (5): wherein Ac represents an acetyl group, the process comprising steps of: subjecting a 2-methyl-2,6-heptadiene compound (1) having a leaving group X at position 1: wherein X represents an acyloxy group having 1 to 10 carbon atoms including the carbon atom of the carbonyl group, an alkanesulfonyloxy group having 1 to 10 carbon atoms, an arenesulfonyloxy group having 6 to 20 carbon atoms, or a halogen atom, to a nucleophilic substitution reaction with a 3-methylpentyl nucleophilic reagent (2) having a protected hydroxyl group at position 5: wherein M represents Li, MgZ.sup.1, ZnZ.sup.1, Cu, CuZ.sup.1, or CuLiZ.sup.1, wherein Z.sup.1 represents a halogen atom or a CH.sub.2CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.2OR group, and R represents a protecting group for a hydroxyl group, to form a 6-isopropenyl-3-methyl-9-decene compound (3) having a protected hydroxyl group at position 1: wherein R is as defined above; subjecting the 6-isopropenyl-3-methyl-9-decene compound (3) having the protected hydroxyl group at position 1 to a deprotection reaction to form 6-isopropenyl-3-methyl-9-decenol (4); and acetylating 6-isopropenyl-3-methyl-9-decenol (4) to form 6-isopropenyl-3-methyl-9-decenyl acetate (5).

##STR00001##

The present disclosure relates to an azobenzene-graphene metal coordination solar photothermal energy storage material based on metal coordination bonds and a preparation method thereof. The method comprises the following steps: preparing reduced graphene oxide; preparing an azobenzene-graphene material; and preparing an azobenzene-graphene metal coordination solar photothermal energy storage material: dispersing the prepared azobenzene-graphene material in DMF, dissolving a certain amount of metal compound in DMF, adding the DMF solution of the metal compound into the DMF solution of the azobenzene-graphene, taking out the precipitate, washing off metal ions which do not participate in coordination, and drying the obtained product to obtain the azobenzene-graphene metal coordination solar photothermal energy storage material. The present disclosure also relates to a method for improving the solar photothermal energy storage ability of a molecular solar energy fuel, comprising using an azobenzene-graphene metal coordination solar photothermal energy storage material.

A solid catalyst component for the polymerization of olefins CH.sub.2═CHR in which R is hydrogen or a hydrocarbon radical with 1-12 carbon atoms, made from or containing Mg, Ti, Bi, halogen and an electron donor obtained from a process including the steps: (a) dissolving a Mg(OR).sub.2 compound wherein R groups, equal to or different from each other, are C.sub.1-C.sub.15 hydrocarbon groups optionally containing a heteroatom selected from O, N and halogen, in an organic liquid medium, thereby forming a first liquid mixture; (b) contacting the first liquid mixture (a) with TiCl.sub.4, thereby forming a second liquid mixture absent a solid phase, and (c) subjecting the second liquid mixture (b) to conditions, whereby solid catalyst particles are formed, wherein (i) a Bi compound and (ii) a bidentate electron donor compound are present in one or more of steps (a) to (c) and/or contacted with the solid catalyst particles obtained from (c).

A solid catalyst component for the polymerization of olefins CH.sub.2═CHR in which R is hydrogen or a hydrocarbon radical with 1-12 carbon atoms, made from or containing Mg, Ti, Bi, halogen and an electron donor obtained from a process including the steps: (a) dissolving a Mg(OR).sub.2 compound wherein R groups, equal to or different from each other, are C.sub.1-C.sub.15 hydrocarbon groups optionally containing a heteroatom selected from O, N and halogen, in an organic liquid medium, thereby forming a first liquid mixture; (b) contacting the first liquid mixture (a) with TiCl.sub.4, thereby forming a second liquid mixture absent a solid phase, and (c) subjecting the second liquid mixture (b) to conditions, whereby solid catalyst particles are formed, wherein (i) a Bi compound and (ii) a bidentate electron donor compound are present in one or more of steps (a) to (c) and/or contacted with the solid catalyst particles obtained from (c).

Disclosed are adsorption complexes that include 1-methylcyclopropene (1-MCP) and a metal coordination polymer network (MCPN), wherein the MCPN is a porous material, and the 1-MCP is adsorbed into the MCPN. Also disclosed are kits for containing 1-MCP that include the adsorption complex in a 1-MCP-impermeable package. Also disclosed are methods of releasing 1-methylcyclopropene (1-MCP) from the kit that include the application of aqueous fluids, heat, and/or pressure.

Disclosed are adsorption complexes that include 1-methylcyclopropene (1-MCP) and a metal coordination polymer network (MCPN), wherein the MCPN is a porous material, and the 1-MCP is adsorbed into the MCPN. Also disclosed are kits for containing 1-MCP that include the adsorption complex in a 1-MCP-impermeable package. Also disclosed are methods of releasing 1-methylcyclopropene (1-MCP) from the kit that include the application of aqueous fluids, heat, and/or pressure.

The present invention relates to a novel magnesium-serinate compound and the use thereof, and more particularly, to a novel magnesium-serinate compound in which a magnesium atom is chelated to L-serine, and the pharmaceutical use thereof against central nervous system diseases or the like. It was confirmed that the novel magnesium-serinate composition obtained by the production method of the present invention consisted of about 10% magnesium and about 90% serine, as determined by instrumental analysis, was solubilized at a concentration of about 500 mg/ml in water at room temperature at a pH of 6.0 to 10.0, was maintained in an aqueous solution state without forming a precipitate, and was also solubilized at a concentration of about 500 mg/ml in phosphate-buffered saline (PBS) solution at room temperature without forming a precipitate. Thus, the novel magnesium-serinate composition has properties suitable for administration orally or by injection to the human body. In addition, the compound activates mitochondrial function and neuronal cell proliferation by increasing the oxygen consumption rate of mitochondria, and exhibits a neuronal protective effect of inhibiting neuronal cell death resulting from mitochondrial membrane potential damage and/or endoplasmic reticulum stress caused by oxidative stress, and exhibits improved blood-brain barrier permeability. Therefore, the compound has an excellent effect on the prevention, treatment and alleviation of central nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, and thus is a highly useful invention in the pharmaceutical industry, etc.

The present invention relates to a novel magnesium-serinate compound and the use thereof, and more particularly, to a novel magnesium-serinate compound in which a magnesium atom is chelated to L-serine, and the pharmaceutical use thereof against central nervous system diseases or the like. It was confirmed that the novel magnesium-serinate composition obtained by the production method of the present invention consisted of about 10% magnesium and about 90% serine, as determined by instrumental analysis, was solubilized at a concentration of about 500 mg/ml in water at room temperature at a pH of 6.0 to 10.0, was maintained in an aqueous solution state without forming a precipitate, and was also solubilized at a concentration of about 500 mg/ml in phosphate-buffered saline (PBS) solution at room temperature without forming a precipitate. Thus, the novel magnesium-serinate composition has properties suitable for administration orally or by injection to the human body. In addition, the compound activates mitochondrial function and neuronal cell proliferation by increasing the oxygen consumption rate of mitochondria, and exhibits a neuronal protective effect of inhibiting neuronal cell death resulting from mitochondrial membrane potential damage and/or endoplasmic reticulum stress caused by oxidative stress, and exhibits improved blood-brain barrier permeability. Therefore, the compound has an excellent effect on the prevention, treatment and alleviation of central nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, and thus is a highly useful invention in the pharmaceutical industry, etc.